ALXN Alexion Pharmaceuticals Inc.
NewsSee all news
-
François Nader, M.D., Joins Moderna's Board of Directors
Former CEO of NPS Pharmaceuticals brings broad expertise to support Moderna's progress towards late-stage development and commercialization
-
Alexion Issues Statement on Path to Value Creation
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today issued the following statement on behalf of the Board of Directors and management team: "The Board and management team are focused on delivering long-term
-
Alexion to Present at the 2019 Evercore ISI HealthCONx
Alexion Pharmaceuticals (NASDAQ:ALXN) today announced that management will present at the 2019 Evercore ISI HealthCONx in Boston, MA on Tuesday, December 3rd, 2019 at 8:45 a.m. ET. An audio webcast of the presentation
-
SOLIRIS® (eculizumab) Receives Approval in Japan for the Prevention of Relapse in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
- SOLIRIS® (eculizumab) is the first and only approved medication for NMOSD in Japan - - 98% of adult anti-aquaporin-4 (AQP4) antibody-positive patients treated with SOLIRIS were relapse free compared to 63% receiving
-
Alexion to Present at the 2019 Stifel Healthcare Conference
Alexion Pharmaceuticals (NASDAQ:ALXN) today announced that management will present at the 2019 Stifel Healthcare Conference in New York, NY on Tuesday, November 19th, 2019 at 8:35 a.m. ET. An audio webcast of the
Drug Information
Drug catalyst information is displayed when you hover over / tap on the stage bar graph.
Latest News
-
François Nader, M.D., Joins Moderna's Board of Directors
Former CEO of NPS Pharmaceuticals brings broad expertise to support Moderna's progress towards late-stage development and commercialization
-
Alexion Issues Statement on Path to Value Creation
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today issued the following statement on behalf of the Board of Directors and management team: "The Board and management team are focused on delivering long-term
-
Alexion to Present at the 2019 Evercore ISI HealthCONx
Alexion Pharmaceuticals (NASDAQ:ALXN) today announced that management will present at the 2019 Evercore ISI HealthCONx in Boston, MA on Tuesday, December 3rd, 2019 at 8:45 a.m. ET. An audio webcast of the presentation
-
SOLIRIS® (eculizumab) Receives Approval in Japan for the Prevention of Relapse in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
- SOLIRIS® (eculizumab) is the first and only approved medication for NMOSD in Japan - - 98% of adult anti-aquaporin-4 (AQP4) antibody-positive patients treated with SOLIRIS were relapse free compared to 63% receiving
-
Alexion to Present at the 2019 Stifel Healthcare Conference
Alexion Pharmaceuticals (NASDAQ:ALXN) today announced that management will present at the 2019 Stifel Healthcare Conference in New York, NY on Tuesday, November 19th, 2019 at 8:35 a.m. ET. An audio webcast of the
-
Fortress Biotech Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights
NEW YORK, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and
-
Achillion Reports Third Quarter 2019 Financial Results and Provides Corporate Update
– Reached an agreement to be acquired by Alexion; transaction expected to close in first half of 2020 – – Danicopan (ACH-4471) received Breakthrough Therapy designation for treatment of PNH; Phase 2
-
Alexion Announces Data Presentations at 61st American Society of Hematology Annual Meeting
- Accepted abstracts include presentations of ULTOMIRIS® (ravulizumab-cwvz) Phase 3 PNH data through 52 weeks - - ULTOMIRIS is the first and only long-acting C5 complement inhibitor, now available in the U.S. for the
-
Alexion Receives FDA Approval for ULTOMIRIS® (ravulizumab-cwvz) for Atypical Hemolytic Uremic Syndrome (aHUS)
- At 26 weeks, 54% of adults and 71% of children treated with ULTOMIRIS demonstrated Complete Thrombotic Microangiopathy (TMA) Response - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the U.S. Food
-
Alexion Announces Appointment of Tanisha Carino, Ph.D., as Chief Corporate Affairs Officer
- Dr. Carino to head up newly integrated Corporate Affairs function including global government affairs, public policy and communications - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the appointment of
-
Alexion and Stealth Announce Agreement for Option to Co-Develop and Commercialize Late-Stage Therapy for Mitochondrial Diseases
- Elamipretide in Phase 3 development for primary mitochondrial myopathy - - If option is exercised, Alexion & Stealth will co-develop and co-promote subcutaneous elamipretide in U.S. & Alexion will receive
-
Alexion to Report Third Quarter 2019 Results On Wednesday, October 23, 2019
Alexion Pharmaceuticals (NASDAQ:ALXN) today announced that the Company will report its financial results for the third quarter ended September 30, 2019 before the US financial markets open on October 23, 2019. Following
-
Alexion Announces CFO Succession
- Aradhana Sarin, M.D., to become CFO after filing of Q3 2019 results - - Paul Clancy to step down as CFO and serve as senior advisor through mid-2020 - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced
-
Alexion and BridgeBio Announce Japanese License Agreement for Eidos' Transthyretin Amyloidosis (ATTR) Investigational Medicine
- Eidos grants Alexion exclusive license to develop and commercialize AG10 in Japan - - Phase 3 study of AG10 in ATTR cardiomyopathy underway in U.S. & Europe; Phase 3 trial in ATTR polyneuropathy planned to
-
Alexion to Present at the 17th Annual Morgan Stanley Global Healthcare Conference
Alexion Pharmaceuticals (NASDAQ:ALXN) today announced that management will present at the 17th Annual Morgan Stanley Global Healthcare Conference in New York, NY on Monday, September 9th, 2019 at 8:45 a.m. ET. An
-
Alexion Announces Upcoming Data Presentations at 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- Five abstracts accepted, including new long-term data from PREVENT trial of SOLIRIS® (eculizumab) in adults with anti-AQP4 antibody-positive NMOSD - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that
-
Alexion to Present at the 14th Annual Citi Biotech Conference
Alexion Pharmaceuticals (NASDAQ:ALXN) today announced that management will present at the 14th Annual Citi Biotech Conference in Boston, MA on Wednesday, September 4th, 2019 at 12:00 p.m., ET. An audio webcast of the
-
European Commission Approves SOLIRIS® (eculizumab) For the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder (NMOSD)
- SOLIRIS® (eculizumab) is the first and only approved medication for NMOSD in Europe - - 98% of adult anti-aquaporin-4 (AQP4) antibody-positive patients treated with SOLIRIS were relapse free compared to 63%
-
European Commission Approves SOLIRIS® (eculizumab) For the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder (NMOSD)
- SOLIRIS® (eculizumab) is the first and only approved medication for NMOSD in Europe - - 98% of adult anti-aquaporin-4 (AQP4) antibody-positive patients treated with SOLIRIS were relapse free compared to 63%